# US 11,304,923 B2 · Use of a benzoate containing composition to treat glycine encephalopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,923 B2
- Document ID: US11304923B2
- Status: Granted
- Kind: B2
- Application number: 16/648,422
- Filed: 2018-09-26
- Published: 2020-09-10
- Granted: 2022-04-19
- Earliest claimed: 2017-10-06
- Assignees: Rush University Medical Center
- Applicants: Rush University Medical Center
- Inventors: Kalipada Pahan
- Web page: https://patentgrep.com/patent/US11304923B2

## CPC

- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to pharmaceutical compositions and formulations useful for inhibiting the progression of glycine encephalopathy. The pharmaceutical compositions and formulations may include glyceryl tribenzoate. The pharmaceutical compositions and formulations may include glyceryl dibenzoate. The pharmaceutical compositions and formulations may be orally administered to the patient.

## Claims

### Claim 1

A method for inhibiting the progression of glycine encephalopathy, comprising: administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising glyceryl tribenzoate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered to the patient one time per day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the effective amount is from about 1.25 grams to about 15 grams per day, based on a 50 kg patient.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is formulated together with a pharmaceutically acceptable carrier or excipient.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered orally.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises glyceryl dibenzoate.

### Claim 7

A method for inhibiting the progression of glycine encephalopathy, comprising: administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising glyceryl dibenzoate.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition comprises glyceryl tribenzoate.

### Claim 9 (depends on 7)

The method of claim 7, wherein the pharmaceutical composition is administered to the patient one time per day.

### Claim 10 (depends on 7)

The method of claim 7, wherein the effective amount is from about 1.25 grams to about 15 grams per day, based on a 50 kg patient.

### Claim 11 (depends on 7)

The method of claim 7, wherein the pharmaceutical composition is formulated together with a pharmaceutically acceptable carrier or excipient.

### Claim 12 (depends on 7)

The method of claim 7, wherein the pharmaceutical composition is administered orally.

### Claim 13

A method of using a formulation for inhibiting the progression of glycine encephalopathy, comprising: administering to a patient in need thereof an effective amount of the formulation, the formulation comprising about 1 gram/1 ml of glyceryl tribenzoate.

### Claim 14 (depends on 13)

The method of claim 13, wherein the formulation is selected from the group consisting of a sustained-release formulation and a delayed-release formulation.

### Claim 15 (depends on 13)

The method of claim 13, wherein the formulation is administered orally to the patient.

### Claim 16 (depends on 13)

The method of claim 13, wherein from about 1.25 grams to about 15 grams per day, based on a 50 kg patient, of the glyceryl tribenzoate are administered to the patient.